NCT00636298撤回2 期
Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Progression-free survival
研究概览
简要总结
The purpose of this study is to test the drug bevacizumab in combination with cetuximab. Because this combination has not been tested in cancer patients before, results will be analyzed to see what effects the combination of bevacizumab with cetuximab has on esophageal cancer.
详细描述
Cancer of the esophagus often has a poor outcome since many patients have advanced disease when they are diagnosed. The average survival rate after five years has increased from 4% in the 1970s to around 14% currently.
Surgery to remove the tumor or treatment with radiotherapy alone has led to disappointing results for patients. Chemotherapy has some activity in patients with advanced disease, although responses are usually short. New strategies are trying to combine these three treatment approaches to improve survival for these patients.
This study will test the combination of cetuximab and bevacizumab in patients with locally advanced esophageal cancer. This is a group of patients with usually poor outcomes from treatment with surgery, radiotherapy or chemotherapy alone. Scientifically, this study will help assess the value in combining these two different types of drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed squamous cell carcinoma or esophageal adenocarcinoma.
- •The disease must be recurrent after first line systemic therapy, with or without radiation, with or without surgery.
- •Patients must be at least 1 month from prior chemotherapy or radiation therapy.
- •ECOG performance status ≤ 1 (Karnofsky > 60%)
- •Life expectancy of greater than 12 weeks.
- •Patients must have normal bone marrow and other organ function or defined below:
- •Absolute neutrophil count, > 1, 500/μL
- •Platelet counts, > 100, 00/μL
- •_ Hemoglobin, > 8.0 gm/dL-
- •Creatinine(< 1.5mg/dL)
- •No significant intercurrent medical illness (including NYHA class II, III or IV heart disease, significant arrhythmias requiring medication, symptomatic coronary artery disease, myocardial infarction within the previous 6 months.
- •Women of childbearing potential must have a negative pregnancy test.
- •Ability to understand and willingness to sign a written informed consent document.
排除标准
- •I. Disease-specific Exclusions
- •All histologic types other than squamous cell carcinoma or adenocarcinoma.
- •Patients currently receiving other investigational agents, or who have received cetuximab previously.
- •Patients with known brain metastases.
- •History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to Cetuximab or Bevacizumab.
- •Patients with history of any other malignancy (except non-melanomatous skin cancer or CIS of cervix) are ineligible unless a period of 5 years has lapsed since treatment of the previous cancer and the patient has remained continuously disease free.
- •Patients who are felt to be poorly compliant.
- •Women who are breast-feeding.
- •II. General Medical Exclusions
- •Subjects meeting any of the following criteria are ineligible for study entry:
- •Inability to comply with study and/or follow-up procedures.
- •Life expectancy of less than 12 weeks.
- •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study.
- •III. Bevacizumab-Specific Exclusions
- •Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure >100 mmHg on antihypertensive medications).
- •Any prior history of hypertensive crisis or hypertensive encephalopathy.
- •New York Heart Association (NYHA) Grade II or greater congestive heart failure
- •History of myocardial infarction or unstable angina within 6 months prior to study enrollment.
- •History of stroke or transient ischemic attack within 6 months prior to study enrollment.
- •Known CNS disease.
- •Significant vascular disease (e.g., aortic aneurysm, aortic dissection).
- •Symptomatic peripheral vascular disease.
- •Evidence of bleeding diathesis or coagulopathy.
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study.
- •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment.
- •Serious, non-healing wound, ulcer, or bone fracture.
- •Proteinuria at screening as demonstrated by either
- •Urine protein: creatinine (UPC) ratio ≥ 1.0 at screening OR
- •Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible)
- •Known hypersensitivity to any component of bevacizumab.
- •Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential.
- •History of myocardial infarction or unstable angina within 6 months of study enrollment.
研究组 & 干预措施
A
Experimental
Single arm treatment with combination of cetuximab and bevacizumab
干预措施: Bevacizumab, cetuximab (Drug)
结局指标
主要结局
Progression-free survival
时间窗: Every 3 months
次要结局
- Response rate(Every 3 months)
研究者
Nabil F. Saba
Principal Investigator
Emory University
相似试验
已完成
2 期
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerHead and Neck CancerSquamous Cell CarcinomaNCT00409565National Cancer Institute (NCI)48
已完成
2 期
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell CarcinomaHead and Neck CancerNCT00968435Memorial Sloan Kettering Cancer Center30
进行中（未招募）
不适用
A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid - CBI-GBMRecurrent or progressive primary GBM in patients with performance status (PS) 0-2.EUCTR2006-000182-10-DKRigshospitalet, Finsen Center32
已完成
2 期
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater AdenocarcinomaAmpulla of Vater AdenocarcinomaSmall Intestinal AdenocarcinomaStage III Ampulla of Vater Cancer AJCC v8Stage III Small Intestinal Adenocarcinoma AJCC v8Stage IIIA Ampulla of Vater Cancer AJCC v8Stage IIIA Small Intestinal Adenocarcinoma AJCC v8Stage IIIB Ampulla of Vater Cancer AJCC v8Stage IIIB Small Intestinal Adenocarcinoma AJCC v8Stage IV Ampulla of Vater Cancer AJCC v8Stage IV Small Intestinal Adenocarcinoma AJCC v8NCT01208103M.D. Anderson Cancer Center30
已完成
2 期
A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal CarcinomaEsophageal CarcinomaNCT00733889Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)50